Table 2 Correlations between GPR30 and EGFR expression and clinicopathological factors
From: GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer
Variables | Expression of GPR30 | p value | Expression of EGFR | p value | ||
|---|---|---|---|---|---|---|
| Ā | Positive | Negative | Ā | Positive | Negative | Ā |
Age | 54.0 Ā± 12.7 | 54.3 Ā± 12.2 | 0.49 | 54.3 Ā±11.9 | 53.9 Ā±13.5 | 0.84 |
Premenopausal | 40 (60.6%) | 26 (39.4%) | 0.80 | 27 (40.9%) | 39 (59.1%) | 0.39 |
Postmenopausal | 60 (60.6%) | 36 (39.4%) | Ā | 33 (33.3%) | 63 (66.7%) | Ā |
BMI | 21.5 Ā± 2.7 | 22.6 Ā± 4.2 | 0.04 | 21.4Ā±3.6 | 22.2Ā±2.8 | 0.11 |
Borderline malignancy | 1 (10.0%) | 9 (90.0%) | 0.0016 | 0 (0%) | 10 (100%) | 0.012 |
FIGO stage I | 26 (66.7%) | 13 (33.3%) | 0.31 | 13 (33.3%) | 26 (66.7%) | 0.77 |
āāāāāII | 11 ( 78.6%) | 3 (21.4%) | Ā | 7 (50.0 %) | 7 (50.0%) | Ā |
āāāāāIII | 47 (61.3%) | 30 (38.7%) | Ā | 32 (41.6%) | 45 (58.4%) | Ā |
āāāāāIV | 15 (68.2%) | 7 (31.8%) | Ā | 8 (36.4%) | 14 (63.6%) | Ā |
Histology | Ā | Ā | Ā | Ā | Ā | Ā |
Borderline malignancy | 1 (10.0%) | 9 (90.0%) | 0.0016 | 0 (0%) | 10 (100%) | 0.012 |
Serous adenocarcinoma | 46 (75.4%) | 15 (24.6%) | <;0.001 | 24 (39.3%) | 37 (60.7%) | 0.42 |
Endometrioid adenocarcinoma | 25 (83.3%) | 5 (16.7%) | Ā | 11 (36.7%) | 19 (63.3%) | Ā |
Mucinous adenocarcinoma | 14 (73.7%) | 5 (26.3%) | Ā | 8 (42.1%) | 11 (57.9%) | Ā |
Clear cell adenocarcinoma | 6 (20.7%) | 23 (79.3%) | Ā | 14 (48.3%) | 15 (51.7%) | Ā |
Others | 8 (61.5%) | 5 (38.5%) | Ā | 3 (23.1%) | 10 (76.9%) | Ā |
Recurrence | Ā | Ā | 0.30 | Ā | Ā | 0.31 |
ā¤ 6M | 13 (68.4%) | 6 (31.6%) | Ā | 9 (47.4%) | 10 (52.6%) | Ā |
> 6M | 43 (67.2%) | 21 (32.8%) | Ā | 20 (31.3%) | 44 (68.7%) | Ā |
No recurrence | 44 (55.7%) | 35 (44.3%) | Ā | 31 (39.2%) | 48 (60.8%) | Ā |
5-year survival | Ā | Ā | 0.56 | Ā | Ā | 0.86 |
Alive | 63 (61.8%) | 39 (38.2%) | Ā | 35 (34.3%) | 67 (65.7%) | Ā |
Dead | 37 (61.7%) | 23 (38.3%) | Ā | 25 (41.7%) | 35 (58.3%) | Ā |